One focus.

Progressing product candidates targeting immune-mediated inflammatory diseases

pipeline Avalo

We are advancing a pipeline that emphasizes a high-value, potentially best-in-class and best-in-disease biologic for an immune-mediated inflammatory disease. Our lead product candidate, AVTX-009, is a high affinity, highly potent humanized IgG monoclonal antibody (mAb) designed to specifically inhibit IL-1β and block downstream inflammatory pathways. AVTX-009 is currently being studied in the LOTUS Phase 2 trial in participants with hidradenitis suppurativa (HS).

Explore the scientific rationale behind targeting IL-1β

AVTX-009: Potential best-in-class and best-in-disease profile in HS

AVTX-009 is an investigational drug being studied as a potential treatment for HS. Because it inhibits IL-1β and blocks inflammatory pathways, AVTX-009 might help control chronic inflammation, nodule and abscess formation, and tissue damage often seen with HS.

Learn about HS and its underlying IL-1β dysregulation
The skin’s complex structure and pressurized environment can limit mAb distribution, often necessitating higher doses for effective target engagement in dermatological conditions such as HS.1,2 However, AVTX-009’s high affinity, potency, and specificity for IL-1β may help overcome this barrier by enabling effective IL-1β inhibition even when tissue penetration is limited.

AVTX-009 in HS3

Lotus logo

The LOTUS Phase 2 trial is currently enrolling

LOTUS is a global, randomized, double-blind Phase 2 trial of AVTX-009 in people with HS.

Discover the LOTUS Trial

References: 1. Ryman JT, Meibohm B. CPT Pharmacometrics Syst Pharmacol. 2017;6:576-588. 2. Witte-Handel E et al. J Invest Dermatol. 2019;139:1294-1305. 3. Bihorel S et al. AAPS J. 2014;16(5):1009-1017. 4. Clinicaltrials.gov. NCT06603077. Accessed November 26, 2024. https://clinicaltrials.gov/study/NCT06603077.

The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.